Top Factor Driving Macular Degeneration Treatment Market Growth in 2025: Growing Retinal Disorder Incidence Propels Macular Degeneration Treatment Market

Which drivers are expected to have the greatest impact on the over the macular degeneration treatment market's growth?
The growth of the macular degeneration treatment market is poised to be catalyzed by the escalating issue of retinal disorders. These disorders compromise a crucial tissue and consequently disrupt the way our eyes process visual input, often resulting in blank or warped vision. For instance, data gathered by the American Academy of Ophthalmology indicates that come 2050, primary open-angle glaucoma-a generic term for a certain category of eye disorders-is predicted to affect roughly 7.32 million individuals in the U.S., with the highest prevalence observed amongst 70 to 79 year olds (32%), females (50%) and the Hispanic demographic (50%). Hispanic men consistently make up the largest group. Hence, the multiplying issues related to retinal disorders are fueling the expansion of the macular degeneration treatment market.

Get Your Macular Degeneration Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What is the future CAGR of the macular degeneration treatment market, and how will it impact industry expansion?
The market for macular degeneration treatment has expanded swiftly in the past few years. The market value is predicted to surge from $11.05 billion in 2024 to $12.42 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 12.4%. Factors such as the aging population, changes in lifestyle, few treatment alternatives, increased awareness, and the development of healthcare infrastructure have contributed to the growth during the historic period.

The market for macular degeneration treatment is slated for accelerated expansion in the coming years, with projections putting it at $19.06 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.3%. This substantial growth in the projected period can be attributed to factors such as advancements in scientific research, higher healthcare spending, increasing instances of the condition, targeted therapeutic strategies, and worldwide initiatives for eye health. The forcecast timeframe will see notable trends such as a shift towards neuroprotective and regenerative therapies, increased use of telemedicine and remote patient monitoring, personalized therapeutic strategies, exploration of stem cell therapy options, and programs aimed at patient awareness and education.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

What are the most significant trends transforming the macular degeneration treatment market today?
Major market players in the field of macular degeneration treatment are heavily investing in the development of biosimilars to enhance access to effective treatments for age-related macular degeneration (AMD). Biosimilars are biological medical products that are essentially identical to an already approved base product, with no signficant variances in their safety, purity, or efficacy. To illustrate, Biocon Biologics Ltd, an India-based firm, and Samsung Bioepis Co. Ltd, a South Korea-originated company, obtained FDA approval for Yesafili and Opuviz, two new biosimilars, in May 2024. These biosimilars obstruct vascular endothelial growth factor (VEGF), which triggers irregular blood vessel growth in the eye. Blocking this action helps to preserve vision in conditions such as AMD and diabetic retinopathy. During the FDA approval process, comprehensive studies were conducted which demonstrated no noticeable differences in effectiveness or safety between Yesafili and Opuviz, and Eylea. The evaluation included rigorous tests to ascertain the biosimilars' pharmacokinetics and immunogenicity.

Which key market segments comprise the macular degeneration treatment market and drive its revenue growth?
The macular degeneration treatment market covered in this report is segmented -

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
3) By Route of Administration: Oral, Injectable, Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:
1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments
2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy
3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799

What regions are at the forefront of macular degeneration treatment market expansion?
North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the macular degeneration treatment market?
Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

What Is Covered In The Macular Degeneration Treatment Global Market Report?

•Market Size Forecast: Examine the macular degeneration treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the macular degeneration treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the macular degeneration treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the macular degeneration treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the macular degeneration treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the macular degeneration treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the macular degeneration treatment market.
•Competitive Landscape: Review strategic developments in the macular degeneration treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.